Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.69 Million GBP | -68.14% |
| 2022 | -3.97 Million GBP | 21.96% |
| 2021 | -5.09 Million GBP | -144.89% |
| 2020 | -2.08 Million GBP | -43.54% |
| 2019 | -1.45 Million GBP | 1.82% |
| 2018 | -1.47 Million GBP | 37.44% |
| 2017 | -2.36 Million GBP | -354.24% |
| 2016 | -519.89 Thousand GBP | -187.43% |
| 2015 | -180.87 Thousand GBP | -2784.78% |
| 2014 | -6270.00 GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1406.42 GBP | 0.0% |
| 2024 Q1 | -1406.42 GBP | -18.71% |
| 2023 Q3 | -1184.79 GBP | 99.97% |
| 2023 FY | -6.69 Million GBP | -68.14% |
| 2023 Q4 | -1184.79 GBP | 0.0% |
| 2023 Q2 | -4.32 Million GBP | -199899.95% |
| 2023 Q1 | -2160.55 GBP | 99.92% |
| 2022 Q1 | -563.84 GBP | 99.96% |
| 2022 FY | -3.97 Million GBP | 21.96% |
| 2022 Q3 | -1425.82 GBP | 99.87% |
| 2022 Q4 | -2.85 Million GBP | -199900.07% |
| 2022 Q2 | -1.12 Million GBP | -199899.82% |
| 2021 Q1 | -1815.57 GBP | 99.85% |
| 2021 FY | -5.09 Million GBP | -144.89% |
| 2021 Q4 | -1.46 Million GBP | -199900.0% |
| 2021 Q3 | -734.04 GBP | 99.98% |
| 2021 Q2 | -3.63 Million GBP | -199900.0% |
| 2020 Q3 | -624.95 GBP | 99.92% |
| 2020 Q2 | -832.31 Thousand GBP | -199900.0% |
| 2020 Q4 | -1.24 Million GBP | -199900.0% |
| 2020 Q1 | -416.16 GBP | 99.94% |
| 2020 FY | -2.08 Million GBP | -43.54% |
| 2019 FY | -1.45 Million GBP | 1.82% |
| 2019 Q4 | -743.95 Thousand GBP | -199899.73% |
| 2019 Q3 | -371.98 GBP | 99.95% |
| 2019 Q2 | -706.67 Thousand GBP | -199900.0% |
| 2019 Q1 | -353.34 GBP | 21.21% |
| 2018 Q3 | -448.45 GBP | -38.53% |
| 2018 Q2 | -323.71 GBP | 0.0% |
| 2018 Q4 | -448.45 GBP | 0.0% |
| 2018 Q1 | -323.71 GBP | 70.89% |
| 2018 FY | -1.47 Million GBP | 37.44% |
| 2017 Q4 | -1112.22 GBP | 0.0% |
| 2017 FY | -2.36 Million GBP | -354.24% |
| 2017 Q1 | -68.59 GBP | 0.0% |
| 2017 Q3 | -1112.22 GBP | -1521.66% |
| 2017 Q2 | -68.59 GBP | 0.0% |
| 2016 FY | -519.89 Thousand GBP | -187.43% |
| 2015 FY | -180.87 Thousand GBP | -2784.78% |
| 2014 FY | -6270.00 GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 91.075% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1.742% |
| SQZ Biotechnologies Company | -79.46 Million USD | 91.58% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 112.629% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 110.272% |
| Mesoblast Limited | -87.95 Million USD | 92.393% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -267.513% |
| Genus plc | 7.9 Million USD | 184.692% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 38.571% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -80.33% |
| Marizyme, Inc. | -65.34 Million USD | 89.761% |
| ContraFect Corporation | -65.15 Million USD | 89.731% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 24.348% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -36.934% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -287.314% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -131.32% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 16.986% |
| MultiCell Technologies, Inc. | -380.07 USD | -1760280.456% |
| Accustem Sciences Inc. | -3.74 Million USD | -78.589% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 87.057% |
| EV Biologics, Inc. | -1.26 Million USD | -428.017% |
| Q BioMed Inc. | -2.05 Million USD | -226.042% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -79.231% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -957.97% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -181.018% |
| Biomind Labs Inc. | -1.21 Million USD | -450.982% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 36.569% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 15.341% |
| Skye Bioscience, Inc. | -37.64 Million USD | 82.227% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -208.353% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -44576.002% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 4.184% |
| IMV Inc. | -36.48 Million USD | 81.662% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 57.845% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -15.014% |
| GB Sciences, Inc. | -1.36 Million USD | -391.356% |
| Alpha Cognition Inc. | -13.77 Million USD | 51.42% |
| HST Global, Inc. | -146.21 Thousand USD | -4476.074% |
| CSL Limited | 2.64 Billion USD | 100.253% |
| Halberd Corporation | -79.67 Thousand USD | -8297.357% |
| Enzolytics Inc. | -2.17 Million USD | -207.358% |
| Resverlogix Corp. | -3.61 Million USD | -85.337% |
| Affymax, Inc. | -14.42 Million USD | 53.614% |
| SYBLEU INC | -180.3 Thousand USD | -3610.776% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -110.967% |
| argenx SE | -295.05 Million USD | 97.732% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 89.312% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 6927.222% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -68.404% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -121.096% |
| AVAX Technologies, Inc. | -6.41 Million USD | -4.319% |
| Zenith Capital Corp. | -10.59 Million USD | 36.857% |
| Genscript Biotech Corporation | -95.47 Million USD | 92.992% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -28687.015% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -61.379% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -10969.839% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 88.798% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -115.705% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -533.553% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -243.244% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -75.195% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -233.681% |
| BioStem Technologies, Inc. | -8.48 Million USD | 21.128% |
| ONE Bio Corp. | 8.67 Million USD | 177.112% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1415.892% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -401.013% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -281.285% |
| Agentix Corp. | -1.37 Million USD | -386.874% |
| LadRx Corporation | 400.44 Thousand USD | 1770.819% |
| Cell Source, Inc. | -5.32 Million USD | -25.736% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1510.353% |
| Regen BioPharma, Inc. | 1.02 Million USD | 753.701% |
| Regen BioPharma, Inc. | 1.02 Million USD | 753.701% |
| NovAccess Global Inc. | -4.76 Million USD | -40.29% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 196.622% |
| Itoco Inc. | -1.86 Million USD | -257.983% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -50.605% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -300.879% |
| Kadimastem Ltd | -3.3 Million USD | -102.294% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2347.194% |
| CytoDyn Inc. | -49.84 Million USD | 86.576% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -8365.676% |
| Mobile Lads Corp. | -2.26 Million USD | -195.617% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2832.874% |
| Qrons Inc. | -789.34 Thousand USD | -747.622% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -610.618% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -220.484% |
| Rebus Holdings, Inc. | -1.02 Million USD | -555.949% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -314.865% |
| International Stem Cell Corporation | -131 Thousand USD | -5007.388% |
| Bioxytran, Inc. | -4.28 Million USD | -56.324% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -12228.048% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -164.428% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 86.082% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -216.494% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -756.805% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -111.196% |
| Neutra Corp. | -233.46 Thousand USD | -2765.816% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 67.026% |
| PureTech Health plc | -65.69 Million USD | 89.816% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 68.539% |
| IXICO plc | -1.17 Million USD | -467.969% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 32.601% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 88.288% |
| CSL Limited | 2.64 Billion USD | 100.253% |
| Cellectis S.A. | -103.17 Million USD | 93.515% |